JP2002510671A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002510671A5 JP2002510671A5 JP2000542291A JP2000542291A JP2002510671A5 JP 2002510671 A5 JP2002510671 A5 JP 2002510671A5 JP 2000542291 A JP2000542291 A JP 2000542291A JP 2000542291 A JP2000542291 A JP 2000542291A JP 2002510671 A5 JP2002510671 A5 JP 2002510671A5
- Authority
- JP
- Japan
- Prior art keywords
- phenoxy
- dimethyl
- naphthyl
- hydroxy
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 43
- 125000001072 heteroaryl group Chemical group 0.000 description 31
- 125000003118 aryl group Chemical group 0.000 description 30
- 125000000217 alkyl group Chemical group 0.000 description 29
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 29
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 19
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 229910052736 halogen Inorganic materials 0.000 description 11
- 150000002367 halogens Chemical class 0.000 description 11
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- 239000005977 Ethylene Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 5
- -1 4-methoxyphenylethylamino Chemical group 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- KSSTVYDZNPHATG-HSZRJFAPSA-N 2-[3-cyano-4-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]phenyl]acetic acid Chemical compound C([C@H](O)CNC(C)(CC=1C=C2C=CC=CC2=CC=1)C)OC1=CC=C(CC(O)=O)C=C1C#N KSSTVYDZNPHATG-HSZRJFAPSA-N 0.000 description 3
- PXCJDRKATHEBOI-HSZRJFAPSA-N 2-[4-cyano-3-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]phenyl]acetic acid Chemical compound C([C@H](O)CNC(C)(CC=1C=C2C=CC=CC2=CC=1)C)OC1=CC(CC(O)=O)=CC=C1C#N PXCJDRKATHEBOI-HSZRJFAPSA-N 0.000 description 3
- IIRPOBZVAYVDPH-HSZRJFAPSA-N 3-[2-cyano-3-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]phenyl]propanoic acid Chemical compound C([C@H](O)CNC(C)(CC=1C=C2C=CC=CC2=CC=1)C)OC1=CC=CC(CCC(O)=O)=C1C#N IIRPOBZVAYVDPH-HSZRJFAPSA-N 0.000 description 3
- BKMZXLKUUMOTKA-XMMPIXPASA-N 3-[3-cyano-4-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]phenyl]propanoic acid Chemical compound C([C@H](O)CNC(C)(CC=1C=C2C=CC=CC2=CC=1)C)OC1=CC=C(CCC(O)=O)C=C1C#N BKMZXLKUUMOTKA-XMMPIXPASA-N 0.000 description 3
- YTSPJXPYPVTZFE-XMMPIXPASA-N 3-[4-cyano-3-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]phenyl]propanoic acid Chemical compound C([C@H](O)CNC(C)(CC=1C=C2C=CC=CC2=CC=1)C)OC1=CC(CCC(O)=O)=CC=C1C#N YTSPJXPYPVTZFE-XMMPIXPASA-N 0.000 description 3
- PKHQFUWTTXDRID-XMMPIXPASA-N 4-[2-cyano-3-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]phenyl]butanoic acid Chemical compound C([C@H](O)CNC(C)(CC=1C=C2C=CC=CC2=CC=1)C)OC1=CC=CC(CCCC(O)=O)=C1C#N PKHQFUWTTXDRID-XMMPIXPASA-N 0.000 description 3
- NUYHDODRHPOQCQ-RUZDIDTESA-N 4-[3-cyano-4-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]phenyl]butanoic acid Chemical compound C([C@H](O)CNC(C)(CC=1C=C2C=CC=CC2=CC=1)C)OC1=CC=C(CCCC(O)=O)C=C1C#N NUYHDODRHPOQCQ-RUZDIDTESA-N 0.000 description 3
- ANDWNEZTVWCWTQ-RUZDIDTESA-N 4-[4-cyano-3-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]phenyl]butanoic acid Chemical compound C([C@H](O)CNC(C)(CC=1C=C2C=CC=CC2=CC=1)C)OC1=CC(CCCC(O)=O)=CC=C1C#N ANDWNEZTVWCWTQ-RUZDIDTESA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- JIBOSOCENSIVSU-RUZDIDTESA-N ethyl 2-[3-cyano-4-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]phenyl]acetate Chemical compound N#CC1=CC(CC(=O)OCC)=CC=C1OC[C@H](O)CNC(C)(C)CC1=CC=C(C=CC=C2)C2=C1 JIBOSOCENSIVSU-RUZDIDTESA-N 0.000 description 3
- PWAWYABZLIUNAD-RUZDIDTESA-N ethyl 2-[4-cyano-3-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]phenyl]acetate Chemical compound CCOC(=O)CC1=CC=C(C#N)C(OC[C@H](O)CNC(C)(C)CC=2C=C3C=CC=CC3=CC=2)=C1 PWAWYABZLIUNAD-RUZDIDTESA-N 0.000 description 3
- PJWYQJZOMUBZBV-RUZDIDTESA-N ethyl 3-[2-cyano-3-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]phenyl]propanoate Chemical compound CCOC(=O)CCC1=CC=CC(OC[C@H](O)CNC(C)(C)CC=2C=C3C=CC=CC3=CC=2)=C1C#N PJWYQJZOMUBZBV-RUZDIDTESA-N 0.000 description 3
- HOWBDMROKCOABA-AREMUKBSSA-N ethyl 3-[3-cyano-4-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]phenyl]propanoate Chemical compound N#CC1=CC(CCC(=O)OCC)=CC=C1OC[C@H](O)CNC(C)(C)CC1=CC=C(C=CC=C2)C2=C1 HOWBDMROKCOABA-AREMUKBSSA-N 0.000 description 3
- ZLRPJEPAEIJOBV-AREMUKBSSA-N ethyl 3-[4-cyano-3-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]phenyl]propanoate Chemical compound CCOC(=O)CCC1=CC=C(C#N)C(OC[C@H](O)CNC(C)(C)CC=2C=C3C=CC=CC3=CC=2)=C1 ZLRPJEPAEIJOBV-AREMUKBSSA-N 0.000 description 3
- WFBZUHNCOPBPPA-AREMUKBSSA-N ethyl 4-[2-cyano-3-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]phenyl]butanoate Chemical compound CCOC(=O)CCCC1=CC=CC(OC[C@H](O)CNC(C)(C)CC=2C=C3C=CC=CC3=CC=2)=C1C#N WFBZUHNCOPBPPA-AREMUKBSSA-N 0.000 description 3
- JVTKSWDOADOJRM-HHHXNRCGSA-N ethyl 4-[3-cyano-4-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]phenyl]butanoate Chemical compound N#CC1=CC(CCCC(=O)OCC)=CC=C1OC[C@H](O)CNC(C)(C)CC1=CC=C(C=CC=C2)C2=C1 JVTKSWDOADOJRM-HHHXNRCGSA-N 0.000 description 3
- SYADYOYIVXAQAO-HHHXNRCGSA-N ethyl 4-[4-cyano-3-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]phenyl]butanoate Chemical compound CCOC(=O)CCCC1=CC=C(C#N)C(OC[C@H](O)CNC(C)(C)CC=2C=C3C=CC=CC3=CC=2)=C1 SYADYOYIVXAQAO-HHHXNRCGSA-N 0.000 description 3
- 230000004079 mineral homeostasis Effects 0.000 description 3
- 0 CC(*)(**B*)N*C(*)(**)*C*c1c(C)c(*)c(*)c(*)c1* Chemical compound CC(*)(**B*)N*C(*)(**)*C*c1c(C)c(*)c(*)c(*)c1* 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 125000005544 phthalimido group Chemical group 0.000 description 2
- GFRUPUKLBSPFJF-OAQYLSRUSA-N 4-[(2r)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]benzoic acid Chemical compound C([C@H](O)CNC(C)(CC=1C=C2C=CC=CC2=CC=1)C)OC1=CC=C(C(O)=O)C=C1 GFRUPUKLBSPFJF-OAQYLSRUSA-N 0.000 description 1
- GPUCXCQJRJRCIE-GOSISDBHSA-N 4-[(2r)-2-hydroxy-3-[[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile Chemical compound C1=CC(OC)=CC=C1CC(C)(C)NC[C@@H](O)COC1=CC=C(C#N)C=C1 GPUCXCQJRJRCIE-GOSISDBHSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8109398P | 1998-04-08 | 1998-04-08 | |
| US60/081,093 | 1998-04-08 | ||
| PCT/US1999/007722 WO1999051569A1 (en) | 1998-04-08 | 1999-04-08 | Calcilytic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002510671A JP2002510671A (ja) | 2002-04-09 |
| JP2002510671A5 true JP2002510671A5 (https=) | 2006-04-20 |
Family
ID=22162059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000542291A Withdrawn JP2002510671A (ja) | 1998-04-08 | 1999-04-08 | カルシウム溶解性化合物 |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US6395919B1 (https=) |
| EP (1) | EP1070048B1 (https=) |
| JP (1) | JP2002510671A (https=) |
| KR (1) | KR20010042526A (https=) |
| CN (1) | CN1304401A (https=) |
| AP (1) | AP1271A (https=) |
| AR (1) | AR018177A1 (https=) |
| AT (1) | ATE303358T1 (https=) |
| AU (1) | AU752389B2 (https=) |
| BG (1) | BG104916A (https=) |
| BR (1) | BR9909486A (https=) |
| CA (1) | CA2327279A1 (https=) |
| CO (1) | CO5031246A1 (https=) |
| DE (1) | DE69927008T2 (https=) |
| DZ (1) | DZ2751A1 (https=) |
| EA (1) | EA200001039A1 (https=) |
| EG (1) | EG24178A (https=) |
| ES (1) | ES2247795T3 (https=) |
| HU (1) | HUP0101346A3 (https=) |
| ID (1) | ID27004A (https=) |
| IL (1) | IL138918A0 (https=) |
| MX (1) | MXPA00009844A (https=) |
| MY (1) | MY121054A (https=) |
| NO (1) | NO20005006D0 (https=) |
| NZ (1) | NZ507288A (https=) |
| OA (1) | OA11499A (https=) |
| PE (1) | PE20000415A1 (https=) |
| PL (1) | PL343357A1 (https=) |
| SK (1) | SK14852000A3 (https=) |
| TR (1) | TR200002896T2 (https=) |
| UA (1) | UA58586C2 (https=) |
| WO (1) | WO1999051569A1 (https=) |
| ZA (1) | ZA200005369B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5180628A1 (es) * | 1999-07-31 | 2002-07-30 | Smithkline Beecham Corp | Compuestos calcioliticos |
| AR030684A1 (es) * | 2000-01-24 | 2003-09-03 | Smithkline Beecham Corp | Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos |
| US20030018203A1 (en) * | 2002-07-17 | 2003-01-23 | Largo Maria Amparo | Calcilytic compounds |
| FR2812875B1 (fr) | 2000-08-08 | 2003-12-12 | Centre Nat Rech Scient | Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation |
| DE60136187D1 (de) | 2000-08-11 | 2008-11-27 | Japan Tobacco Inc | Calciumrezeptor-antagonisten |
| AU2002230579A1 (en) * | 2000-10-25 | 2002-05-06 | Smithkline Beecham Corp | Calcilytic compounds |
| TWI316511B (en) * | 2002-11-26 | 2009-11-01 | Smithkline Beecham Corp | Calcilytic compounds |
| WO2004069793A2 (en) | 2003-01-28 | 2004-08-19 | Bristol-Myers Squibb Company | Novel 2-substituted cyclic amines as calcium sensing receptor modulators |
| US7205322B2 (en) | 2003-02-12 | 2007-04-17 | Bristol-Myers Squibb Company | Thiazolidine compounds as calcium sensing receptor modulators |
| DK1619180T3 (da) * | 2003-04-23 | 2010-03-29 | Japan Tobacco Inc | CaSR-antagonist |
| US7265145B2 (en) | 2003-05-28 | 2007-09-04 | Bristol-Myers Squibb Company | Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method |
| WO2004106280A1 (ja) | 2003-05-28 | 2004-12-09 | Japan Tobacco Inc. | ＣａＳＲアンタゴニスト |
| EP1713758A4 (en) * | 2004-02-06 | 2008-02-13 | Smithkline Beecham Corp | CALCILYTIC COMPOUNDS |
| US7648965B2 (en) * | 2004-05-14 | 2010-01-19 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
| US7531518B2 (en) | 2004-05-14 | 2009-05-12 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
| US20060293667A1 (en) * | 2005-05-19 | 2006-12-28 | Agnes Vignery | Bone implant device and methods of using same |
| ES2400693T3 (es) * | 2005-09-02 | 2013-04-11 | Amgen Inc. | Regulación del equilibrio de fluido intestinal usando calcimiméticos |
| CA2681582C (en) * | 2007-03-30 | 2015-07-14 | Amgen Inc. | Methods of treating bowel disorders |
| ES2412408T3 (es) * | 2008-12-24 | 2013-07-11 | Daiichi Sankyo Company, Limited | Compuestos de indanilo |
| WO2010103429A1 (en) | 2009-03-10 | 2010-09-16 | Pfizer Inc. | 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists |
| GB201217330D0 (en) | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2533210A1 (fr) * | 1982-09-17 | 1984-03-23 | Lyon I Universite Claude | Edulcorants de synthese |
| DE3301198A1 (de) * | 1983-01-15 | 1984-07-19 | Hoechst Ag, 6230 Frankfurt | N-arylalkylamin-3-propoxypyridin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung |
| US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
| KR19990045727A (ko) | 1995-09-21 | 1999-06-25 | 피터 지. 스트링거 | 선택적 β３ 아드레날린 효능제 |
| DE69733649T2 (de) | 1996-04-09 | 2006-05-18 | NPS Pharmaceuticals, Inc., Salt Lake City | Calcylitische verbindungen |
-
1999
- 1999-04-06 MY MYPI99001327A patent/MY121054A/en unknown
- 1999-04-06 PE PE1999000275A patent/PE20000415A1/es not_active Application Discontinuation
- 1999-04-06 AR ARP990101554A patent/AR018177A1/es unknown
- 1999-04-07 EG EG36999A patent/EG24178A/xx active
- 1999-04-07 DZ DZ990052A patent/DZ2751A1/xx active
- 1999-04-08 AT AT99916516T patent/ATE303358T1/de not_active IP Right Cessation
- 1999-04-08 NZ NZ507288A patent/NZ507288A/en not_active IP Right Cessation
- 1999-04-08 CA CA002327279A patent/CA2327279A1/en not_active Abandoned
- 1999-04-08 DE DE69927008T patent/DE69927008T2/de not_active Expired - Lifetime
- 1999-04-08 CN CN99807083A patent/CN1304401A/zh active Pending
- 1999-04-08 EA EA200001039A patent/EA200001039A1/ru unknown
- 1999-04-08 US US09/647,793 patent/US6395919B1/en not_active Expired - Lifetime
- 1999-04-08 AU AU34819/99A patent/AU752389B2/en not_active Ceased
- 1999-04-08 JP JP2000542291A patent/JP2002510671A/ja not_active Withdrawn
- 1999-04-08 KR KR1020007011166A patent/KR20010042526A/ko not_active Ceased
- 1999-04-08 PL PL99343357A patent/PL343357A1/xx not_active Application Discontinuation
- 1999-04-08 HU HU0101346A patent/HUP0101346A3/hu unknown
- 1999-04-08 CO CO99020604A patent/CO5031246A1/es unknown
- 1999-04-08 MX MXPA00009844A patent/MXPA00009844A/es unknown
- 1999-04-08 BR BR9909486-0A patent/BR9909486A/pt not_active Application Discontinuation
- 1999-04-08 ZA ZA200005369A patent/ZA200005369B/xx unknown
- 1999-04-08 ID IDW20002001A patent/ID27004A/id unknown
- 1999-04-08 IL IL13891899A patent/IL138918A0/xx unknown
- 1999-04-08 TR TR2000/02896T patent/TR200002896T2/xx unknown
- 1999-04-08 EP EP99916516A patent/EP1070048B1/en not_active Expired - Lifetime
- 1999-04-08 ES ES99916516T patent/ES2247795T3/es not_active Expired - Lifetime
- 1999-04-08 WO PCT/US1999/007722 patent/WO1999051569A1/en not_active Ceased
- 1999-04-08 SK SK1485-2000A patent/SK14852000A3/sk unknown
- 1999-04-08 AP APAP/P/2000/001931A patent/AP1271A/en active
- 1999-08-04 UA UA2000105670A patent/UA58586C2/uk unknown
-
2000
- 2000-10-04 NO NO20005006A patent/NO20005006D0/no not_active Application Discontinuation
- 2000-10-06 OA OA1200000277A patent/OA11499A/en unknown
- 2000-11-07 BG BG104916A patent/BG104916A/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002510671A5 (https=) | ||
| RU2437877C2 (ru) | Новые производные тиофена в качестве агонистов рецептора s1p1/edg1 | |
| JP2007502806A5 (https=) | ||
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| JP2000514779A (ja) | マトリックスメタロプロティナーゼのスルホンアミド阻害剤 | |
| JP2006501295A5 (https=) | ||
| JPH0840911A (ja) | 骨損失を抑制するための併用療法 | |
| RU2002127781A (ru) | Производные карбоновых кислот в качестве антагонистов ip | |
| JP2010520308A5 (https=) | ||
| CN1297352A (zh) | 有机磷化合物在治疗和预防性治疗感染中的应用 | |
| JP2011527334A5 (https=) | ||
| RU2010128006A (ru) | Производные тиофена в качестве агонистов sipi/edgi | |
| JP4582456B2 (ja) | ８−アザプロスタグランジン誘導体およびその医薬用途 | |
| JP2007500238A5 (https=) | ||
| RU2002135312A (ru) | Средство, усиливающие секрецию гормона роста | |
| CY1110450T1 (el) | Χρησιμοποιηση ενος παραγωγου αλογονιδιου υδροξιμικου οξεος στη θεραπευτικη αγωγη νευροεκφυλιστικων νοσων | |
| RU2003103780A (ru) | Соединения фенилпиридазина и содержащие их лекарственные средства | |
| RU2001135802A (ru) | Антагонисты рецептора брадикинина | |
| CN103380112A (zh) | 作为s1p受体调节剂的吲哚衍生物 | |
| JP2020505354A5 (https=) | ||
| US9597326B2 (en) | Benzonapthyridine compositions and uses thereof | |
| JP2002525323A5 (https=) | ||
| RU2004107261A (ru) | Арилсульфонильные производные, обладающие сродством к рецептору 5-нт6 | |
| JP2006516626A5 (https=) | ||
| RU2004104329A (ru) | Ацилсемикарбазиды как ингибиторы циклинзависимой киназы, полезные в качестве противораковых и противопролиферативных агентов |